Division of Veterinary Clinical Complex, Sher-E-Kashmir University of Agricultural Sciences and Technology of Kashmir, Shalimar, Shuhama, Alusteng, Srinagar, 190006, Jammu and Kashmir, India.
Department of Medicinal and Biological Chemistry, College of Pharmacy and Pharmaceutical Sciences, University of Toledo, Toledo, OH 43614, USA.
CNS Neurol Disord Drug Targets. 2024;23(7):906-916. doi: 10.2174/1871527323666230817102125.
Traumatic brain injury (TBI) is a major healthcare problem and a common cause of mortality and morbidity. Clinical and preclinical research suggests sex-related differences in short- and longterm outcomes following TBI; however, males have been the main focus of TBI research. Females show a protective response against TBI. Female animals in preclinical studies and women in clinical trials have shown comparatively better outcomes against mild, moderate, or severe TBI. This reflects a favorable protective nature of the females compared to the males, primarily attributed to various protective mechanisms that provide better prognosis and recovery in the females after TBI. Understanding the sex difference in the TBI pathophysiology and the underlying mechanisms remains an elusive goal. In this review, we provide insights into various mechanisms related to the anatomical, physiological, hormonal, enzymatic, inflammatory, oxidative, genetic, or mitochondrial basis that support the protective nature of females compared to males. Furthermore, we sought to outline the evidence of multiple biomarkers that are highly potential in the investigation of TBI's prognosis, pathophysiology, and treatment and which can serve as objective measures and novel targets for individualized therapeutic interventions in TBI treatment. Implementations from this review are important for the understanding of the effect of sex on TBI outcomes and possible mechanisms behind the favorable response in females. It also emphasizes the critical need to include females as a biological variable and in sufficient numbers in future TBI studies.
创伤性脑损伤(TBI)是一个主要的医疗保健问题,也是死亡率和发病率的常见原因。临床和临床前研究表明,TBI 后短期和长期结果存在与性别相关的差异;然而,男性一直是 TBI 研究的主要关注点。女性对 TBI 表现出保护反应。在临床前研究中,雌性动物和临床试验中的女性在轻度、中度或重度 TBI 中表现出相对较好的结果。这反映了女性相对于男性的有利保护性质,主要归因于各种保护机制,这些机制为 TBI 后女性提供了更好的预后和恢复。了解 TBI 病理生理学和潜在机制中的性别差异仍然是一个难以实现的目标。在这篇综述中,我们提供了有关与解剖学、生理学、激素、酶、炎症、氧化、遗传或线粒体基础相关的各种机制的见解,这些机制支持女性相对于男性的保护性质。此外,我们试图概述多个生物标志物的证据,这些标志物在 TBI 预后、病理生理学和治疗的研究中具有很高的潜力,可以作为 TBI 治疗中客观测量和新的治疗靶点。本综述中的实施对于理解性别对 TBI 结果的影响以及女性良好反应背后的可能机制非常重要。它还强调了在未来的 TBI 研究中必须将女性作为生物学变量并以足够数量纳入的重要性。